Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial infarction - Contribution of cystatin C assessment

Coronary Artery Disease

Volumn 20, Issue 7, 2009, Pages 453-461

  Derzhko, Roksolana ^a   Plaksej, Rafal ^a   Przewlocka Kosmala, Monika ^a   Kosmala, Wojciech ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Biomarkers; Cystatin C; Echocardiography; Left ventricular dysfunction; Prognosis; ST elevation myocardial infarction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN I;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; ST SEGMENT ELEVATION; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTATIN C; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; STROKE VOLUME; TIME FACTORS; TROPONIN I; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70449496069     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32832fe5ec     Document Type: Article

References (30)

1. Cannon CP, Greenberg BH. Risk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol 2008; 102 (Suppl):13G-20G.
2. Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008; 51:2339-2346.
3. Wu CJ, Chang HW, Hung WC, Yang CH, Chen YH, Su CY, et al. N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2006; 70:163-168.
4. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006; 70:1379-1384.
5. Oltrona L, Ottani F, Galvani M; Italian Working Group on Atherosclerosis, Thrombosis, and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J 2004; 148:405-415.
6. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115:173-179.
7. Larsson A, Helmersson J, Hansson LO, Basu S. Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. Int J Cardiol 2008; 125:263-264.
8. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L, Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110:2342-2348. (Pubitemid 39407337)
9. Mega JL, Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44:335-339.
10. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Simultaneous assessment of troponin I, C-reactive proetin, and B-type natriuretic peptide. Circulation 2002; 105: 1760-1763.
11. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, et al. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide. Tha LAMP (Leicester Acute Myocardial Infarction Peptide) Study. J Am Coll Cardiol 2008; 51:1857-1864.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
13. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
14. Feinberg MS, Schwammenthal E, Shlizerman L, Porter A, Hod H, Freimark D, et al. Prognostic significance of mild mitral regurgitation by color Doppler echocardiography in acute myocardial infarction. Am J Cardiol 2000; 86:903-907.
15. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SWL. Progression of systolic abnormalities in patients with isolated diastolic heart failure and diastolic dysfunction. Circulation 2002; 105:1195-1201.
16. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10:933-989.
17. Bolognese L, Cerisano G. Early predictors of left ventricular remodeling after acute myocardial infarction. Am Heart J 1999; 138:S79-S83.
18. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J 2008; 29:1241-1249.
19. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, et al.; Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007; 194:397-402.
20. De Winter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 2004; 94:1481-1485.
21. Ottani F, Galvani M, Nicolini FA, Ferrini D, Pozzati A, Di Pasquale G, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140:917-927.
22. Bjorklund E, Jernberg T, Johanson P, Venge P, Dellborg M,Wallentin L, et al. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart 2006; 92:735-740.
23. Marenzi G, Moltrasio M, Assanelli E, Lauri G, Marana I, Grazi M, et al. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. Am Heart J 2007; 153:755-762.
24. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108:2769-2775.
25. Ferrer-Hita JJ, Dominguez-Rodriguez A, Garcia-Gonzalez MJ, Abreu-Gonzalez P. Renal dysfunction is an independent predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Int J Cardiol 2007; 118:243-245.
26. Bertomeu-Gonzalez V, Núñez J, Núñez E, Fá cila L, Sanchis J, Bodí V, et al. Prognostic effect of renal dysfunction after ST-segment elevation myocardial infarction with and without heart failure. Int J Cardiol 2006; 112:159-165.
27. Laterza OF, Price CP, Scott MG, Cystatin C. an improved estimator of glomerular filtration rate? Clin Chem 2002; 48:699-707.
28. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40:221-226.
29. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Cardiac Fail 2006; 12:601-607.
30. Tang WHW, van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Cardiac Fail 2008; 14:394-399.